¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"functional terminal innervation ratio"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • relative risk ratio
    »ó´ëÀ§Çèºñ
  • respiratory exchange ratio
    È£Èí±³È¯ºñÀ²
  • risk benefit ratio
    À§ÇèÆíÀͺñ
  • risk ratio
    À§Çèºñ
  • standardized mortality ratio
    Ç¥ÁØÈ­»ç¸Áºñ
  • standardized rate ratio
    Ç¥ÁØÈ­ºñÀ²ºñ
  • stopping power ratio
    ÀúÁö´Éºñ
  • survival ratio
    »ýÁ¸ºñ
  • segregation ratio
    ºÐ¸®ºñ
  • serum urea nitrogen/creatinine ratio
    Ç÷û¿ä¼ÒÁú¼Ò/Å©·¹¾ÆÆ¼´Ñºñ
  • sex ratio
    ¼ººñ
  • signal-to-noise ratio
    ½ÅÈ£´ëÀâÀ½ºñ
  • uptake ratio
    ¼·ÃëÀ²
  • urea excretion ratio
    ¿ä¼Ò¹è¼³ºñ
  • velocity ratio
    ¼Óµµºñ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • depth to width ratio
    ±íÀÌÆøºñÀ²
  • dextrose-nitrogen ratio
    Æ÷µµ´çÁú¼Òºñ
  • dilution ratio
    ¹±Èûºñ, Èñ¼®ºñ
  • disease odds ratio
    Áúº´±³Â÷ºñ
  • distribution ratio
    ºÐÆ÷ºñÀ²
  • exposure ratio
    ³ëÃâºñÀ²
  • exposure-odds ratio
    ³ëÃâ±³Â÷ºñ
  • extraction ratio
    ÃßÃâ·ü
  • ratio estimate
    ºñÀ²ÃßÁ¤°ª
  • fetal death ratio
    žƻç¸Áºñ
  • gas exchange ratio
    °¡½º±³È¯ºñÀ²
  • gyromagnetic ratio
    ȸÀüÀÚ±âºñÀ²
  • heart lung ratio
    ½ÉÆó°è¼ö, ½ÉÀåÈä°ûºñ
  • hydrodynamic ratio
    ¼ö·ÂÇкñÀ²
  • inspiratory expiratory ratio
    µé¼û³¯¼ûºñÀ², ÈíÈ£±â´ëºñ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • functional regurgitation
    ±â´ÉÀû ¿ª·ù.
  • functional residual air =FRA
    ±â´É(Àû) Àܱâ(¡­íÑѨ).
  • functional residual capacity =FRC
    ±â´ÉÀû ÀÜ·ù¿ë·®(íÑ×¶éÄÕá), ±â´ÉÀû Àܱⷮ(íÑѨÕá).
  • hallucination, functional
    ±â´É¼ºÈ¯°¢(ѦÒöàõü³ÊÆ)
  • hearing loss, functional
    ±â´É(¼º) ³­Ã»
  • ileus, functional
    ±â´ÉÀû ÀåÆó»öÁõ, ±â´ÉÀû ÀÏ·¹¿ì½º.
  • inorganic murmur =functional m.
    ±â´ÉÀû ÀâÀ½(ѦÒöîÜíÚëå).
  • reactive functional hypoglycemia
    ¹ÝÀÀ¼º ±â´É¼º ÀúÇ÷´ç(¡­Ñ¦Òöàõî¸úìÓØ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • functional capacity
  • functional cardiovascular disease
    ±â´É¼º ½ÉÇ÷°üº´.
  • functional cause
    ±â´ÉÀû¿øÀÎ
  • functional cell
    ±â´É¼¼Æ÷(ѦÒöá¬øà).
  • functional color blindness
    ±â´É¼º»ö¸Í
  • functional congestion
    ±â´ÉÀû ¿ïÇ÷.
  • functional dead space
    ±â´ÉÀû »ç°­ (¡­ÞÝË·).
  • functional deafness
    ±â´É(¼º) ³­Ã»
  • functional deficiency
    ±â´É°áÇÌ
  • functional derangements
    ±â´ÉÀå¾Ö(ÀÌ»ó)
  • functional disorder
    ±â´É¼º Àå¾Ö.
  • functional dysmenorrhea
    ±â´É¼º ¿ù°æ°ï¶õ(Áõ)(¡­êÅÌèÍÝÑññø).
  • functional dyspepsia
    ±â´É¼º ¼ÒÈ­ºÒ·®.
  • functional endoscopic sinus surgery
    ±â´É(Àû) ³»½Ã°æ ºÎºñµ¿¼ö¼ú
  • functional group
    ÀÛ¿ë±â(íÂéÄÐñ).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
MTF maximum terminal flow; medical treatment facility; modulation transfer function
NT nasotracheal; neotetrazolium; neurotensin; neurotrophic; neutralization test; nicotine tartrate; non...
Nt amino terminal
pFc noncovalently bonded dimer of the C-terminal immunoglobulin of the Fc fragment
TA alkaline tuberculin; arterial tension; axillary temperature; tactile afferent; Takayasu arteritis; t...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
JNK C-Jun amino-terminal kinase
CtBP C-Terminal binding protein
JNK C-jun N-terminal kinase
Csk C-terminal Src Kinase
CTD C-terminal domain
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
amino-terminal residue <biochemistry> The only amino acid residue in a polypeptide chain that has a free alpha-amino group, it defines the amino terminus of the polypeptide.
(09 Oct 1997)
axonal terminal boutons The somewhat enlarged, often club-shaped endings by which axons make synaptic contacts with other nerve cells or with effector cells (muscle or gland cells). As isolated, by homogenizing brain or spinal cord, they contain acetylcholine and the related enzymes. Terminals contain neurotransmitters of various kinds, sometimes more than one. These can be demonstrated by chemical analysis and immunocytochemical methods.
See: synapse.
Synonym: axonal terminal boutons, end-feet, neuropodia, pieds terminaux, synaptic boutons, synaptic endings, synaptic terminals, terminal boutons, bouton terminaux.
(05 Mar 2000)
carboxyl terminal The end of a polypeptide chain with the unattached carboxyl group (a -COOH group). Each amino acid in the middle of the chain has an amino group (a -NH2 group) on one side (which is attached to the carboxyl group of the previous amino acid) and a carboxyl group on the other side (which is attached to the amino group of the next amino acid). The other end of the polypeptide chain is called the amino terminal.
(09 Oct 1997)
carboxyl-terminal residue This amino acid residue defines the carboxylterminus of the polypeptide, its the only residue with a free alpha-carboxyl group.
(09 Oct 1997)
carboxy terminal The end of a peptide or protein having a free carboxyl (-COOH) group.
(05 Mar 2000)
carboxy-terminal domain kinase <enzyme> Protein kinase that phosphorylates the c-terminal repeat domain of the largest subunit of RNA polymerase II at serine residues
Registry number: EC 2.7.1.-
Synonym: ctd kinase, hs-ctd kinase, tfiih-associated ctd kinase
(26 Jun 1999)
central terminal electrode In electrocardiography, an electrode in which connections from the three limbs (right arm, left arm, and left leg) are joined and led to the electrocardiograph to form the indifferent electrode, theoretically at zero potential for the system.
(05 Mar 2000)
RNA 3'-terminal phosphate cyclase <enzyme> ATP dependent; forms 2',3' terminal cyclic phosphate on RNA which is then the substrate for RNA ligase of hela cells
Registry number: EC 6.5.-
Synonym: RNA tph cyclase
(26 Jun 1999)
c-Jun amino-terminal kinase <enzyme> A stress-activated protein kinase; 46-kD kinase that phosphorylates ser(63) and ser(73) of c-jun; similar to yeast hog1 kinase; amino acid sequence given in second source; genbank l23118
Registry number: EC 2.7.10.-
Synonym: jn kinase, jnk1 protein kinase, jnk-46, jnk1 protein, jun-nh2-terminal kinase, stress-activated protein kinase 1, sap kinase-1, sapk1, p46 sap kinase, c-jun kinase-1
(26 Jun 1999)
photosystem II D1 polypeptide carboxy-terminal processing protease <enzyme> From thylakoids; not inhibited by common protease inhibitors
Registry number: EC 3.4.99.-
Synonym: d1 carboxy-terminal processing protease, d1 c-terminal protease, ctpa gene product
(26 Jun 1999)
COOH-terminal signal transamidase <enzyme> Present in the endoplasmic reticulum; catalyses concomitant cleavage of the signal peptide of nascent proteins destined to be processed to a glycosylphosphatidylinositol (gpi) and addition of the gpi anchor
Registry number: EC 2.3.2.-
Synonym: cooh-ts-transamidase, gpi transamidase, gpti transamidase
(26 Jun 1999)
C-terminal leucine protein methyltransferase <enzyme> Reversibly modifies protein phosphatase 2a by methyl esterification at its c-terminal leucine residues
Registry number: EC 2.1.1.-
Synonym: tlp methyltransferase
(26 Jun 1999)
protein NH2-terminal asparagine deamidase <enzyme> Converts amino terminal asparagine to aspartic acid; from porcine liver; mw about 33 kD
Registry number: EC 3.5.1.-
Synonym: porcine pnad
(26 Jun 1999)
protein N-terminal acetyltransferase <enzyme> From saccharmyces cerevisiae; encodes a catalytic subunit of an n-terminal acetyltransferase; ard1 and nat1 proteins are subunits of this enzyme
Registry number: EC 2.3.1.-
Synonym: nat1 gene protein, saccharomyces, yeast protein n-terminal acetyltransferase, n-terminal protein acetyltransferase, ard1 protein
(26 Jun 1999)
HIV long-terminal repeat Regulatory sequences important for viral replication that are located on each end of the HIV genome. The ltr includes the HIV enhancer, promoter, and other sequences. Specific regions in the ltr include the negative regulatory element (nre), nf-kappa b binding sites , sp1 binding sites, tata box, and trans-acting responsive element (tar). The binding of both cellular and viral proteins to these regions regulates HIV transcription.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
ÅëÇÕ°Ë»ö ¿Ï·á